Nano Formulations as Drug Delivery Systems

Year 2022, Volume: 4 Issue: 2, 90 - 103, 31.07.2022

Sema Yılmaz , Yelda Komesli

Abstract

Classical drug forms are used frequently and in repeated doses. Undesirable situations may occur when the dose used for the concentration of the active substance released into the system falls below the sufficient amount or rises above the toxic level. As a result of the developments achieved in nanotechnological research, nanoparticles, which have many applications in the clinic, have made a significant impact in the pharmaceutical industry. The practical use of nanoparticles in applications such as direct binding to the active substance, entrapment and targeting in the pharmaceutical industry has made nanoparticles a preferred position. When implanted systems with nanocarriers reach the target area, uptake in organs, tissues and cells increases. These structures use active and passive targeting strategies to deliver the active substance to the targeted cells. The use of nanocarriers in drug delivery systems provides many advantages. The results obtained from the studies carried out so far are that, thanks to the targeting of cancer drug-loaded nanocarriers, treatment alternatives with higher selectivity have emerged. In this study, nanoparticles as drug delivery are discussed and how to increase bioavailability with nanoparticles is discussed with their advantages.

Keywords

nano particles, nanotechnology, drug delivery systems

References

• Allen, L., & Ansel, H. C. (2013). Ansel's pharmaceutical dosage forms and drug delivery systems. Lippincott Williams & Wilkins.
• Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews, 65(1), 36-48.
• Anwekar, H., Patel, S., & Singhai, A. K. (2011). Liposome-as drug carriers. International journal of pharmacy & life sciences, 2(7).
• Asgher, M., Qamar, S. A., & Iqbal, H. (2021). Microbial exopolysaccharide-based nano-carriers with unique multi-functionalities for biomedical sectors. Biologia, 76(2), 673-685. Deirram, N., Zhang, C., Kermaniyan, S. S., Johnston, A. P., & Such, G. K. (2021). pH‐responsive polymer nanoparticles for drug delivery. Macromolecular rapid communications, 40(10), 1800917.
• Derman S, Kızılbey K, Akdeste Z., (2013). Polymerıc Nanopartıcles. Journal of Engineering and Natural Sciences Mühendislik ve Fen Bilimleri Dergisi Sigma; 31, 109- 122.
• Dong, X. (2018). Current strategies for brain drug delivery. Theranostics, 8(6), 1481.
• Dreaden, E. C., Alkilany, A. M., Huang, X., Murphy, C. J., & El-Sayed, M. A. (2012). The golden age: gold nanoparticles for biomedicine. Chemical Society Reviews, 41(7), 2740-2779.
• Eşim, Ö. (2020). Platine dirençli over kanseri tedavisine yönelik nanopartiküler ilaç taşıyıcı sistemlerin geliştirilmesi ve değerlendirilmesi.
• Fung, L. K., & Saltzman, W. M. (1997). Polymeric implants for cancer chemotherapy. Advanced drug delivery reviews, 26(2-3), 209-230.
• Francia, V., Reker-Smit, C., Boel, G., & Salvati, A. (2019). Limits and challenges in using transport inhibitors to characterize how nano-sized drug carriers enter cells. Nanomedicine, 14(12), 1533-1549.
• Ge, X., Wei, M., He, S., & Yuan, W. E. (2019). Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics, 11(2), 55.
• Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G., & Misra, A. (2014). PEG—a versatile conjugating ligand for drugs and drug delivery systems. Journal of controlled release, 192, 67-81.
• Kontermann, R. (2012, March). Dual targeting strategies with bispecific antibodies. In MAbs (Vol. 4, No. 2, pp. 182-197). Taylor & Francis.